4.8 Article

Linking the p53 tumour suppressor pathway to somatic cell reprogramming

Journal

NATURE
Volume 460, Issue 7259, Pages 1140-1144

Publisher

NATURE PORTFOLIO
DOI: 10.1038/nature08311

Keywords

-

Funding

  1. Astellas Pharma Inc
  2. Japan Society for the Promotion of Science
  3. NIH [5 R01 CA061449, CA100845]
  4. Leila Y. Mathers Charitable Foundation and Fundacion Cellex
  5. ICREA Funding Source: Custom

Ask authors/readers for more resources

Reprogramming somatic cells to induced pluripotent stem (iPS) cells has been accomplished by expressing pluripotency factors and oncogenes(1-8), but the low frequency and tendency to induce malignant transformation(9) compromise the clinical utility of this powerful approach. We address both issues by investigating the mechanisms limiting reprogramming efficiency in somatic cells. Here we show that reprogramming factors can activate the p53 (also known as Trp53 in mice, TP53 in humans) pathway. Reducing signalling to p53 by expressing a mutated version of one of its negative regulators, by deleting or knocking down p53 or its target gene, p21 (also known as Cdkn1a), or by antagonizing reprogramming-induced apoptosis in mouse fibroblasts increases reprogramming efficiency. Notably, decreasing p53 protein levels enabled fibroblasts to give rise to iPS cells capable of generating germline-transmitting chimaeric mice using only Oct4 ( also known as Pou5f1) and Sox2. Furthermore, silencing of p53 significantly increased the reprogramming efficiency of human somatic cells. These results provide insights into reprogramming mechanisms and suggest new routes to more efficient reprogramming while minimizing the use of oncogenes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available